146 related articles for article (PubMed ID: 37776537)
1. Combined BRAF, MEK, and heat-shock protein 90 inhibition in advanced BRAF V600-mutant melanoma.
Eroglu Z; Chen YA; Smalley I; Li J; Markowitz JK; Brohl AS; Tetteh L; Taylor H; Sondak VK; Khushalani NI; Smalley KSM
Cancer; 2024 Jan; 130(2):232-243. PubMed ID: 37776537
[TBL] [Abstract][Full Text] [Related]
2. Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study.
Ribas A; Gonzalez R; Pavlick A; Hamid O; Gajewski TF; Daud A; Flaherty L; Logan T; Chmielowski B; Lewis K; Kee D; Boasberg P; Yin M; Chan I; Musib L; Choong N; Puzanov I; McArthur GA
Lancet Oncol; 2014 Aug; 15(9):954-65. PubMed ID: 25037139
[TBL] [Abstract][Full Text] [Related]
3. Combined BRAF and HSP90 Inhibition in Patients with Unresectable
Eroglu Z; Chen YA; Gibney GT; Weber JS; Kudchadkar RR; Khushalani NI; Markowitz J; Brohl AS; Tetteh LF; Ramadan H; Arnone G; Li J; Zhao X; Sharma R; Darville LNF; Fang B; Smalley I; Messina JL; Koomen JM; Sondak VK; Smalley KSM
Clin Cancer Res; 2018 Nov; 24(22):5516-5524. PubMed ID: 29674508
[No Abstract] [Full Text] [Related]
4. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.
Dummer R; Ascierto PA; Gogas HJ; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; Chiarion-Sileni V; Dutriaux C; de Groot JWB; Yamazaki N; Loquai C; Moutouh-de Parseval LA; Pickard MD; Sandor V; Robert C; Flaherty KT
Lancet Oncol; 2018 May; 19(5):603-615. PubMed ID: 29573941
[TBL] [Abstract][Full Text] [Related]
5. Extended 5-Year Follow-up Results of a Phase Ib Study (BRIM7) of Vemurafenib and Cobimetinib in
Ribas A; Daud A; Pavlick AC; Gonzalez R; Lewis KD; Hamid O; Gajewski TF; Puzanov I; Wongchenko M; Rooney I; Hsu JJ; Yan Y; Park E; McArthur GA
Clin Cancer Res; 2020 Jan; 26(1):46-53. PubMed ID: 31732523
[TBL] [Abstract][Full Text] [Related]
6. Atezolizumab, cobimetinib, and vemurafenib as first-line treatment for unresectable metastatic BRAF V600 mutated melanoma.
Schmitt AM; Dumas L; Larkin J
Expert Rev Anticancer Ther; 2022 Jan; 22(1):17-25. PubMed ID: 34904502
[TBL] [Abstract][Full Text] [Related]
7. Phase 1 study of the combination of vemurafenib, carboplatin, and paclitaxel in patients with BRAF-mutated melanoma and other advanced malignancies.
Bhatty M; Kato S; Piha-Paul SA; Naing A; Subbiah V; Huang HJ; Karp DD; Tsimberidou AM; Zinner RG; Hwu WJ; Javle M; Patel SP; Hu MI; Varadhachary GR; Conley AP; Ramzanali NM; Holley VR; Kurzrock R; Meric-Bernstam F; Kwang Chae Y; Kim KB; Falchook GS; Janku F
Cancer; 2019 Feb; 125(3):463-472. PubMed ID: 30383888
[TBL] [Abstract][Full Text] [Related]
8. Atezolizumab, vemurafenib, and cobimetinib in patients with melanoma with CNS metastases (TRICOTEL): a multicentre, open-label, single-arm, phase 2 study.
Dummer R; Queirolo P; Abajo Guijarro AM; Hu Y; Wang D; de Azevedo SJ; Robert C; Ascierto PA; Chiarion-Sileni V; Pronzato P; Spagnolo F; Mujika Eizmendi K; Liszkay G; de la Cruz Merino L; Tawbi H
Lancet Oncol; 2022 Sep; 23(9):1145-1155. PubMed ID: 35940183
[TBL] [Abstract][Full Text] [Related]
9. Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial.
Ascierto PA; McArthur GA; Dréno B; Atkinson V; Liszkay G; Di Giacomo AM; Mandalà M; Demidov L; Stroyakovskiy D; Thomas L; de la Cruz-Merino L; Dutriaux C; Garbe C; Yan Y; Wongchenko M; Chang I; Hsu JJ; Koralek DO; Rooney I; Ribas A; Larkin J
Lancet Oncol; 2016 Sep; 17(9):1248-60. PubMed ID: 27480103
[TBL] [Abstract][Full Text] [Related]
10. Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial.
Dummer R; Ascierto PA; Gogas HJ; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; Chiarion Sileni V; Dutriaux C; de Groot JWB; Yamazaki N; Loquai C; Moutouh-de Parseval LA; Pickard MD; Sandor V; Robert C; Flaherty KT
Lancet Oncol; 2018 Oct; 19(10):1315-1327. PubMed ID: 30219628
[TBL] [Abstract][Full Text] [Related]
11. Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients.
Sullivan RJ; Hamid O; Gonzalez R; Infante JR; Patel MR; Hodi FS; Lewis KD; Tawbi HA; Hernandez G; Wongchenko MJ; Chang Y; Roberts L; Ballinger M; Yan Y; Cha E; Hwu P
Nat Med; 2019 Jun; 25(6):929-935. PubMed ID: 31171876
[TBL] [Abstract][Full Text] [Related]
12. Modeled Prognostic Subgroups for Survival and Treatment Outcomes in BRAF V600-Mutated Metastatic Melanoma: Pooled Analysis of 4 Randomized Clinical Trials.
Hauschild A; Larkin J; Ribas A; Dréno B; Flaherty KT; Ascierto PA; Lewis KD; McKenna E; Zhu Q; Mun Y; McArthur GA
JAMA Oncol; 2018 Oct; 4(10):1382-1388. PubMed ID: 30073321
[TBL] [Abstract][Full Text] [Related]
13. The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms.
Paraiso KH; Haarberg HE; Wood E; Rebecca VW; Chen YA; Xiang Y; Ribas A; Lo RS; Weber JS; Sondak VK; John JK; Sarnaik AA; Koomen JM; Smalley KS
Clin Cancer Res; 2012 May; 18(9):2502-14. PubMed ID: 22351686
[TBL] [Abstract][Full Text] [Related]
14. Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAF
Ascierto PA; Stroyakovskiy D; Gogas H; Robert C; Lewis K; Protsenko S; Pereira RP; Eigentler T; Rutkowski P; Demidov L; Zhukova N; Schachter J; Yan Y; Caro I; Hertig C; Xue C; Kusters L; McArthur GA; Gutzmer R
Lancet Oncol; 2023 Jan; 24(1):33-44. PubMed ID: 36460017
[TBL] [Abstract][Full Text] [Related]
15. BRIM-P: A phase I, open-label, multicenter, dose-escalation study of vemurafenib in pediatric patients with surgically incurable, BRAF mutation-positive melanoma.
Chisholm JC; Suvada J; Dunkel IJ; Casanova M; Zhang W; Ritchie N; Choi Y; Park J; Das Thakur M; Simko S; Wan Rachel Tam N; Ferrari A
Pediatr Blood Cancer; 2018 May; 65(5):e26947. PubMed ID: 29350463
[TBL] [Abstract][Full Text] [Related]
16. Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAF
Gutzmer R; Stroyakovskiy D; Gogas H; Robert C; Lewis K; Protsenko S; Pereira RP; Eigentler T; Rutkowski P; Demidov L; Manikhas GM; Yan Y; Huang KC; Uyei A; McNally V; McArthur GA; Ascierto PA
Lancet; 2020 Jun; 395(10240):1835-1844. PubMed ID: 32534646
[TBL] [Abstract][Full Text] [Related]
17. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C
Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819
[TBL] [Abstract][Full Text] [Related]
18. A phase I/II study of LY3022855 with BRAF/MEK inhibition in patients with Melanoma.
Buchbinder EI; Giobbie-Hurder A; Haq R; Ott PA
Invest New Drugs; 2023 Aug; 41(4):551-555. PubMed ID: 37247116
[TBL] [Abstract][Full Text] [Related]
19. Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma.
Ascierto PA; Dummer R; Gogas HJ; Flaherty KT; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; de Groot JWB; Loquai C; Gollerkeri A; Pickard MD; Robert C
Eur J Cancer; 2020 Feb; 126():33-44. PubMed ID: 31901705
[TBL] [Abstract][Full Text] [Related]
20. [Ocular toxicity of targeted therapies with MEK inhibitors and BRAF inhibitors in the treatment of metastatic cutaneous melanoma].
Fauviaux E; Promelle V; Boucenna V; Jany B; Errera MH; Delbarre M; Boucenna W
J Fr Ophtalmol; 2022 Jun; 45(6):612-618. PubMed ID: 35501194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]